Nuclear envelope budding enables export of large transcripts in muscle cells

FierceBiotechErasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death

FierceBiotechIncyte’s JAK inhibitor scores phase 3 vitiligo wins but can’t quite shake off Rinvoq

FierceBiotechAbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

FierceBiotechProtagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits

CellGlobal genetic interaction network of a human cell maps conserved principles and informs functional interpretation of gene co-essentiality profiles

CellStabilizing MARCH7 as a ferro-guardian against ferroptosis

BioPharma DiveBoehringer dual-acting obesity shot hits mark in Phase 3 trial

BioWorldRead BioWorld's AACR 2026 coverage

Endpoints NewsRocket's PRV goes for $180M; Oruka targets $500M offering

Endpoints NewsBeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF

Endpoints NewsIncyte claims double Phase 3 win in vitiligo, will file for approval

BioPharma DiveFDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results